Partial
Partially Aligned
Patient Risk:
Low
Summary
Only the weight-management indication claim is supported by the provided label excerpt; the remaining claims (patents, pricing/availability, manufacturer, drug-class comparisons, other products, and generic-legal production statements) are not supported by the supplied FDA prescribing information and, in the absence of additional label sections, cannot be confirmed as label-accurate.
Category Scores
Accurate Statements
Zepbound is approved for weight management.
Supported by label section 1 INDICATIONS AND USAGE (reduced-calorie diet and increased physical activity; to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight with at least one weight-related comorbid condition).
Unsupported Statements
The cost of generic Zepbound has not yet been established.
Not supported by the provided FDA label excerpts.
Zepbound is under patent protection.
Not supported by the provided FDA label excerpts.
Zepbound is manufactured by Eli Lilly.
Not supported by the provided FDA label excerpts.
Zepbound is in the same drug class as Mounjaro.
Not supported by the provided FDA label excerpts.
Mounjaro is approved for type 2 diabetes management.
Not supported by the provided FDA label excerpts (and refers to a different product).
Zepbound is protected by patents, meaning generic versions cannot be legally produced until these patents expire.
Not supported by the provided FDA label excerpts.
The specific patent expiration dates for Zepbound are not publicly available.
Not supported by the provided FDA label excerpts.
Zepbound is currently only available as a brand-name medication.
Not supported by the provided FDA label excerpts.
The list price of Zepbound is approximately $1,060 per month for a four-week supply.
Pricing information is not supported by the provided FDA label excerpts.
Actual out-of-pocket costs for Zepbound can vary significantly depending on insurance coverage, pharmacy, and any available discount programs or coupons.
Not supported by the provided FDA label excerpts.
Eli Lilly offers savings cards that can reduce the cost of Zepbound for eligible commercially insured patients.
Not supported by the provided FDA label excerpts.
Wegovy is an alternative weight management medication.
Not supported by the provided FDA label excerpts.
Wegovy contains semaglutide.
Not supported by the provided FDA label excerpts.
Wegovy is from Novo Nordisk.
Not supported by the provided FDA label excerpts.
Saxenda is an alternative weight management medication.
Not supported by the provided FDA label excerpts.
Saxenda contains liraglutide.
Not supported by the provided FDA label excerpts.
Saxenda is from Novo Nordisk.
Not supported by the provided FDA label excerpts.
Phentermine-topiramate is available as Qsymia.
Not supported by the provided FDA label excerpts.
Mounjaro shares the same active ingredient as Zepbound (tirzepatide).
Not supported by the provided FDA label excerpts.
Pharmaceutical companies obtain patents for new drugs to grant them exclusive rights to manufacture and sell their products for a set period.
Not supported by the provided FDA label excerpts.
Once a patent expires, other companies can apply to the U.S. Food and Drug Administration (FDA) to market generic versions of the drug.
Not supported by the provided FDA label excerpts.
Generic versions are typically less expensive.
Not supported by the provided FDA label excerpts.
Contradictions
Important Omissions
No FDA label-supported dosage/administration details, contraindications, boxed warnings, warnings/precautions, drug interactions, adverse reactions, monitoring, or population-specific information were evaluated because the provided claim set does not include such label content.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The only label-supported clinical claim provided is the weight-management indication; other claims are largely non-label market/patent/cost/alternate-product statements and do not directly add dosing or safety instructions. However, inability to confirm broader safety-label alignment limits the overall certainty.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Most claims are not supported by the supplied FDA prescribing information excerpts (patent/legal, pricing/availability, manufacturer, and other-product comparisons).
Suggested Improvement
Restrict Zepbound-specific statements to content present in FDA labeling (e.g., Indications) and omit or clearly separate non-label topics such as pricing, patent/legal status, generic availability, and competitor product details unless the corresponding FDA label text is provided.